Mesoblast (ASX:MSB) - Managing Director and CEO, Silviu Itescu (centre)
Managing Director and CEO, Silviu Itescu (centre)
Source: Mesoblast
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mesoblast (MSB) has raised US$90 million (A$138 million) to manufacture its cell therapy treatment for COVID-19 patients with respiratory failure
  • Last month, the company found its treatment was 83 per cent effective against COVID-19 patients with acute respiratory distress syndrome (ARDS)
  • Mesoblast issued 43 million shares to existing and new institutional investors at a price of $3.20 per share
  • Majority of the funds will be used to scale-up manufacturing, while the remaining fund will be used for working capital and corporate purposes
  • Mesoblast is down 4.07 per cent on the market this morning, trading for $3.30 per share

Mesoblast (MSB) has raised US$90 million (A$138 million) to manufacture its cell therapy treatment, remestemcel-L treatment, for COVID-19 patients.

Last month, the company found its treatment was 83 per cent effective against COVID-19 patients with acute respiratory distress syndrome (ARDS).

The trial showed that 75 per cent of the COVID-19 patients had successfully come off ventilator support around 10 days after the treatment.

In contrast, one New York hospital network only saw a 12 per cent survival rate using the standard of care within the same period Mesoblast treated its patients.

Placement

Mesoblast issued 43 million shares to existing and new institutional investors at a price of $3.20 per share.

The majority of the funds will be used to scale-up manufacturing of remestemcel-L for the treatment of critically ill patients suffering from diseases caused by cytokine release syndromes associated with high mortality, particularly COVID-19.

The remaining funds will be used for working capital and general corporate purposes.

“We greatly appreciate the support shown by both our existing investors and new institutional investors, with demand for the placement far exceeding the funds raised,” Chief Executive Dr Silviu Itescu said.

“We look forward to updating the market as this important COVID-19 ARDS trial progresses and to its completion in the coming months,” he added.

Mesoblast is down 4.07 per cent on the market this morning, trading for $3.30 per share at 11:24 am AEST.

MSB by the numbers
More From The Market Online
Disability NDIS concept

Freedom Care Group reveals NDIS wants to ban it providing program services

Shares in Freedom Care Group (ASX:FCG) were down more than -3% on Wednesday after revealing the…
Image representing bacterial infections in the immune system

Recce reaches key dosing milestone in testing of skin infection gel

Recce Pharmaceuticals Ltd has successfully dosed 20 out of 30 participants in its Phase II trial…
Bank of England London town

Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health…
DNA RNA therapy concept

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11,…